医療薬学
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
一般論文
フェキソフェナジンあるいはベポタスチンの前投薬によるリツキシマブ投与時のinfusion reaction発現抑制効果
松井 頌明石原 慎之望月 優里玉木 宏樹西村 信弘直良 浩司
著者情報
ジャーナル 認証あり

2019 年 45 巻 7 号 p. 396-403

詳細
抄録

Since infusion reaction (IR) frequently occurs in rituximab (RTX) therapy, premedication of antipyretic analgesics and histamine 1 (H1) receptor antagonists before RTX administration is essential. However, there are no standard drugs for H1 receptor antagonists. There is a possibility that H1 receptor antagonists with various pharmacokinetic properties have different preventive/suppressive effects against IR. In this study, we conducted a retrospective study on patients who received RTX first dose with premedication of fexofenadine (n = 31) or bepotastine (n = 33), the second generation H1 receptor antagonist, to compare the inhibitory effects of both drugs on IR occurrence. The incidence of IR was 58.1% in the fexofenadine-administered group and 21.2% in the bepotastine-administered group with a significant difference. The IR occurrence time (median) was 65 min after RTX administration in both groups. Multivariate logistic regression analysis indicated that the fexofenadine-administered group is an independent risk factor to increase the risk of IR occurrence by 8.3 times compared with the bepotastine-administered group. Since fexofenadine takes a longer time to reach maximum blood concentration (Tmax) than bepotastine, it is considered that the different effect on IR prevention in both drugs may be caused by the difference in Tmax. Based on these results, it was suggested that H1 receptor antagonists to be administered before RTX administration should be selected taking their pharmacokinetic properties into consideration.

著者関連情報
© 2019 日本医療薬学会
前の記事 次の記事
feedback
Top